Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2018-08-09 16:33:06
Reporting Period:
Accepted Time:
2018-08-09 16:33:06
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1368514 Adma Biologics Inc. ADMA Biological Products, (No Disgnostic Substances) (2836) 562590442
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1748876 Trust Divestiture Biotest 402 Norfolk St.
Cambridge MA 02139
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Non-Voting Common Stock Disposition 2018-05-14 8,591,160 $0.00 0 No 4 S Indirect By Biotest Pharmaceuticals Corporation
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Biotest Pharmaceuticals Corporation
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 10,109,534 Indirect By Biotest Pharmaceuticals Corporation
  1. On May 14, 2018, pursuant to a Share Transfer, Amendment and Release Agreement, by and among the issuer, Biotest AG, Biotest Pharmaceuticals Corporation ("BPC"), Biotest US Corporation ("Biotest US"), and The Biotest Devestiture Trust (the "Trust"), BPC transferred to the issuer, for no cash consideration, 8,591,160 shares of the issuer's non-voting common stock previously issued to BPC in June 2017 and representing 100% of the issuer's then-issued and outstanding non-voting common stock.
  2. Represents securities owned by BPC. BPC is a wholly-owned subsidiary of Biotest US, which is wholly-owned by the Trust. Eric Rosenbach, the trustee of the Trust, is the sole director of each of BPC and Biotest US and has voting and investment discretion with respect to the securities of the issuer held by BPC. Mr. Rosenbach has no pecuniary interest in such securities.